Contingent Consideration - Additional Information (Detail) - USD ($)			3 Months Ended	12 Months Ended
	Nov. 03, 2020	Jul. 12, 2019	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Future contingent payments			$ 5,390,000	$ 5,390,000	$ 2,750,000
Change in value of contingent consideration for acquired in-process research and development				$ 16,265,010
Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Up-front consideration	$ 13,600,000
Consideration amount	$ 9.57
Shares issued for contingent milestone payment	1,694,906
Period for submission of clinical trial notification	60 days
Submission date of clinical trial notification	Oct. 29, 2020
Regulatory Milestones [Member] | Clinical Trial Notification [Member]
Business Acquisition [Line Items]
Change in value of contingent consideration for acquired in-process research and development			$ 5,400,000
Spitfire Pharma, Inc. [Member]
Business Acquisition [Line Items]
Agreement date		Jul. 08, 2019
Unregistered shares of common stock		1,887,250
Up-front consideration		$ 5,000,000			4,300,000
Transaction cost recorded within research and development expense					700,000
In-process research and development costs					$ 2,800,000
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application Milestone [Member]
Business Acquisition [Line Items]
Future contingent payments		$ 5,000,000
Future contingent payment term		60 days
Number of consecutive trading days		20 days
Consideration amount		$ 2.95
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application and Regulatory Milestones [Member]
Business Acquisition [Line Items]
Future contingent payments		$ 3,000,000
Future contingent payment term		60 days
Number of consecutive trading days		20 days
Consideration amount		$ 3.54
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member]
Business Acquisition [Line Items]
Future contingent payments		$ 80,000,000
License agreement term		10 years
Spitfire Pharma, Inc. [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Upfront consideration release at 3 months		50.00%
Upfront consideration release at 6 months		50.00%
Spitfire Pharma, Inc. [Member] | Common Stock [Member] | Maximum [Member]
Business Acquisition [Line Items]
Future contingent payments		$ 88,000,000